Bio Open Lab: Q&A w/ D1ckGPT & VitaStem + BioXP Updates

BioProtocol avatar
Bio Protocol
@BioProtocolOct 3, 2025

The Spaces covered two major launches on Bio alongside a comprehensive overhaul of the Bio XP system. Clip (CPO, Bio Protocol) announced a pause of engagement (“yapping”) rewards due to bot farming, the activation of XP expiration next week (FIFO deprecation), and an upcoming reweighting of veBIO and ecosystem staking with multipliers that favor long-term stakers—constituting a new “season” for XP. James (Head of Science) framed these adjustments as the scientific method in action, driven by community feedback. Sun and co-founder Dr. Ake introduced DickGPT, a urologist‑curated AI agent focused on men’s sexual health, aiming to provide personalized, evidence‑based guidance, build the largest men’s health data hub, and enable on-chain trials; its token launches via Bio V2 Ignition. Dr. Ashish presented VitaStem, an IP token project to rejuvenate hematopoietic stem cells (HSCs) for healthier aging. Using ~850k single‑cell profiles (ages 23–91), he identified ~150 targets and, with the Aubrey AI agent, prioritized ~10 for in vitro testing, saving substantial time and cost versus traditional review. The session closed with logistics: both DickGPT and VitaStem sales go live tomorrow via Ignition, requiring BIO tokens and Bio XP.

Bio Protocol Twitter Spaces – Ignition Launches, Bio XP Reset, and Two New Science Agents

Participants and Roles

  • Adam – Head of Marketing at Molecule; host and moderator.
  • Sun – Medical doctor (Thailand), co‑founder of dGPT (men’s sexual health AI agent project).
  • Clip – CPO, Bio Protocol; leads tech and protocol.
  • James – Head of Science, Bio Protocol.
  • Ashish – Principal Investigator for VitaStem IP project; neuroscientist/cancer biologist with iPSC/stem cell background.
  • Ake – Co‑founder of dGPT; thoracic surgeon; collaborator is a urologist and men’s sexual health clinic owner.

Program Updates: Bio XP, Engagement, and Staking

Why changes are happening (Clip)

  • The team is reworking the entire Bio XP system (engagement “yapping” rewards, asset staking rewards, and overall distribution) based on observed data.
  • Problem statement: Over time, engagement incentives attracted increasing bot/farming activity that’s progressively harder to distinguish from genuine users given rapid AI advances.

Immediate actions

  • Yapping rewards paused: Engagement reward payouts are stopped for an undefined period while the team redesigns the system.
  • Last batch distributed: A final distribution (“last season/interval”) has been sent; typical yapping rewards have historically been ~5–10% of total Bio XP issued over a given window.

Points expiration and “reset”

  • Expiration is being turned on early next week after the two imminent Ignition sales.
  • First-in, first-out expiration: Older unspent points will be removed in a one-time “purge,” leveling the playing field for newer participants and preventing indefinite point accumulation via refunds.
  • Implication for users: The two upcoming Ignition sales are the last opportunities to apply legacy XP before expiration.

Staking incentives (veBIO and ecosystem assets)

  • veBIO staking rewards have effectively diluted per staked BIO due to rising participation; Bio will re-center staking as a core XP-earning pillar.
  • Proposed change: Introduce multipliers tied to veBIO holdings, with veBIO increasing linearly with lock duration (longer lockups reward more than short, large-amount stakes). Example principle: a smaller amount locked for longer can approach the impact of a larger amount locked briefly.
  • New “season” of Bio XP earnings will launch with these changes; team will monitor effects on staked ecosystem assets and BIO.

Process and philosophy (James)

  • The team frames these changes as iterative, scientific optimization: hypothesis → experiment → data → parameter tuning.
  • Strong community feedback is viewed as a positive signal indicating engagement and co-building with users.

Upcoming Ignition Sales: What’s Launching and Timing

  • Two launches planned for “tomorrow” (per Adam):
    • dGPT token (men’s sexual health AI agent).
    • VitaStem IP Token (HSC rejuvenation project).
  • Participation requirements: Users need BIO tokens and Bio XP to commit into the Ignition sales and secure allocations.
  • Timing note: These are the final two sales before XP expiration is enabled; users are urged to spend legacy XP now.

dGPT: Men’s Sexual Health AI Agent and Token Launch

Vision and scope (Sun)

  • North Star: Use an AI agent engine (urologist‑curated knowledge base) to analyze, evaluate, and guide men toward healthier sexual function and overall health; aggregate the world’s largest men’s health data hub.
  • Problem size: 4 billion men worldwide; Sun cites estimates that ~40–50% have at least one sexual health issue (e.g., erectile dysfunction [ED], low testosterone, infertility, premature ejaculation).
  • Stigma and neglect: Men tend to avoid care due to taboo/shame; medical systems often classify men’s sexual health as “benign urologic conditions,” deprioritizing research and comprehensive treatment.
  • Funding gap: Sun asserts men’s sexual health received effectively no NIH funding in 2025, reflecting systemic neglect relative to other major NCDs, which see frequent guideline updates and new therapies.

Limitations of current solutions

  • Many telemedicine offerings are not truly personalized: users pick from a few preset options and are routed to quick fixes (e.g., sildenafil/tadalafil) without root-cause workups.
  • Analogy: Treating chronic cough with symptomatic cough syrup rather than investigating etiology.
  • Risks in unregulated markets (Ake): Harmful practices (e.g., subdermal injections of silicone/oils) and supplements adulterated with PDE5 inhibitors expose users to serious health risks, especially with comorbidities.

Root causes and holistic approach (Ake)

  • ED and performance issues reflect interconnected systems: hormones (e.g., testosterone), psychological factors, cardiovascular health, sleep, diet, and exercise.
  • ED is often an early marker of broader vascular/metabolic disease; improving sexual health can signal or drive improvements in overall health and longevity.

The dGPT solution

  • AI agent trained on a urologist-curated database and evidence-based protocols.
  • Personalized recommendations based on individual history, risk profile, lifestyle, budget, and time constraints.
  • Screening system: Team has developed an internal screening framework (“DH”) and reports ~12,000 accesses to their test to date; objective is to learn from aggregate data, refine guidance, and orchestrate on‑chain trials.
  • Long-term goal: Enable safe, evidence-based interventions and potentially develop new products; build the data and community needed to discover the “next Viagra” on-chain.

Token launch mechanics and positioning (Sun, Adam)

  • Launch venue: Bio V2 Launchpad via Ignition sale.
  • Access: Bio XP holders can commit BIO and points to qualify for allocations; designed to reward active Bio community members before open-market trading.
  • Historical context: Previous Bio agents reportedly delivered strong returns (first agent ~300x; second ~30–40x). These are cited as context, not guarantees.
  • Timeline: Launch targeted for tomorrow; framed as a “new beginning” for men’s health.

VitaStem IP Token: Rejuvenating Hematopoietic Stem Cells (HSCs)

Scientific rationale and objectives (Ashish)

  • Target: Hematopoietic stem cells (HSCs) in bone marrow, critical for lifelong blood and immune cell production (oxygen delivery, immune competence, tissue repair).
  • Aging phenotype: HSC functional decline → impaired hematopoiesis, anemia, myeloid skewing, reduced regenerative capacity, poor vaccine responses in older adults.
  • Strategy: Rejuvenate resident HSCs in vivo rather than transplantation (to avoid risks like graft‑versus‑host disease and invasive procedures ill‑suited for broad, healthy aging applications).

Data-driven discovery

  • Dataset: ~850,000 single-cell transcriptomes across donors aged 23–91, combining public and proprietary data.
  • Output: High-resolution atlas of hematopoietic aging and ~150 candidate genes as potential rejuvenation factors.
  • Bottleneck: Prioritizing candidates for wet-lab validation and translational potential.

Role of the Aubrey AI agent (Bio’s scientific co‑pilot)

  • Validation and triage: Aubrey AI confirmed the core hypothesis and helped prioritize ~10 top gene targets for in vitro testing.
  • Efficiency: Ashish estimates saving roughly $500k in exploratory protocol work and significant time by leveraging the agent’s curated knowledge and reference retrieval.
  • Scope: Aubrey AI suggested experimental protocols, highlighted small molecules that could modulate targets (repurposing opportunities), and provided development-status intel (e.g., originating company, stage) to inform target selection.
  • Reliability: Compared to general LLMs (e.g., ChatGPT), Aubrey minimized hallucinations and provided better-cited, domain-accurate guidance.

Experimental plan and translational path

  • In vitro validation: Test prioritized gene interventions in primary young and aged human HSCs.
  • Models: Organoids and “human-on-a-chip” systems; CRISPR-based activation/inhibition; mRNA overexpression (electroporation), siRNA/antisense where appropriate.
  • Small molecules: Parallel discovery/repurposing to enable practical, targeted delivery to HSCs.
  • Goal: “Safe rejuvenation” that improves aging phenotypes without dedifferentiation.

Contrast with Yamanaka factors (OSKM)

  • OSKM can reprogram somatic cells to pluripotency but carries high risk without precise control (dedifferentiation, loss of identity).
  • VitaStem aims for tunable, controlled partial rejuvenation—reversing aging hallmarks without changing cell lineage (e.g., preventing bone marrow cells from becoming unrelated cell types).

Potential impact

  • Even a 10–15% rejuvenation effect in HSCs could materially improve outcomes in older adults: mitigate myeloid skewing, restore adaptive immunity (T/B cells), improve vaccine responsiveness, reduce anemia and age-related disease burden.

Funding mechanism and launch

  • Origin: Concept incubated via VitaDAO’s Vita Labs (up to $50k grants for longevity projects).
  • Progression: Participated in Bio’s Hypothesis Challenge; submitted refined proposal via BioOperator/IPT funding for next-phase work.
  • Launch: VitaStem IP Token planned to go live on Bio’s Ignition (same window as dGPT’s launch), marking Bio Protocol’s second IP token.

Bio Agents: Scientific Co‑Pilots

  • Bio Agents are specialized AI agents infused with expert knowledge (e.g., Aubrey AI incorporates the writings and expertise of Dr. Aubrey de Grey plus broader scientific literature), serving as research copilots to:
    • Generate and refine hypotheses.
    • Analyze datasets.
    • Propose experimental protocols.
    • Surface curated references and translational pathways.
  • Reported outcomes include significant cost and time savings, higher-quality hypothesis triage, and reduced risk of LLM hallucinations in scientific workflows.

Calls to Action and Key Timelines

  • Two Ignition sales tomorrow: dGPT token and VitaStem IP Token.
  • Requirements: Stake BIO and eligible ecosystem assets to earn Bio XP; you need BOTH BIO and Bio XP to participate/commit.
  • Last chance for legacy XP: Spend points in these two sales—expiration (FIFO) will purge unspent, older points early next week.
  • Engagement rewards paused: Yapping rewards are on hold; a redesigned engagement system will be announced later (no fixed ETA).
  • Staking incentives: veBIO multiplier changes coming; a new Bio XP “season” will begin with the updated distribution model.

Notable Highlights

  • Program governance: Bio explicitly treats program design as a scientific process, iterating based on real data and community feedback.
  • Market framing (dGPT): Men’s sexual health is a massive, under‑served domain with stigma and systemic neglect; dGPT aims to bring evidence‑based, personalized care and catalyze on‑chain clinical discovery.
  • Translational science (VitaStem): A data-rich, AI-accelerated path to partial HSC rejuvenation targets; a practical alternative to full reprogramming that seeks meaningful, safer gains in immune health with age.
  • Community-first launches: Ignition advantages engaged Bio participants (Bio XP holders) before open-market trading.

Closing Sentiment

  • Team gratitude for community feedback and participation; optimism about an “exciting week ahead.”
  • Strong emphasis on using remaining XP in the imminent sales, then preparing for the refreshed Bio XP season and staking-driven incentives.